Lynne Peterson is the Senior Writer for Trends-in-Medicine.
Here is the medical news to watch for September 6-12, 2021.
Cardiology: The hybrid Heart Failure Society of America (HFSA) meeting will take place in Denver (proof of vaccination required) and virtually September 10-13. Among the data to be presented at a late-breaking clinical trial session are:
- An analysis of the failed PARADISE-MI trial, looking at health status post-myocardial infarction after Novartis’ Entresto (sacubitril + valsartan), an ARNI, vs. an ACE inhibitor.
- GALACTIC-HF trial of Cytokinetics’ omecamtiv mecarbil, a cardiac myosin activator, in black patients with heart failure with reduced ejection fraction (HFrEF).
- REDWOOD-HCM trial of an oral cardiac myosin inhibitor, Cytokinetics’ aficamten (CK-3773274) in obstructive hypertrophic cardiomyopathy.
- Another SGLT2 inhibitor in heart failure – the PRESERVED-HF trial of dapagliflozin (AstraZeneca’s Farxiga).
- A mineralocorticoid receptor antagonist (MRA) – finerenone (Bayer’s Kerendia) – to reduce eGFR decline in patients with both diabetes and mild-to-severe chronic kidney disease (CKD).
- First-in-human data on a gene therapy (Rocket Pharmaceuticals’ RP-A501) for Danon disease.
Hepatology: The Conference on Liver Disease in Africa (COLDA) will take place virtually September 9-11. There will be an update on hepatitis, a discussion of diagnostics and prevention during Covid-19, an assessment of maternal-fetal transmission of hepatitis B virus (HBV), reports from various African countries – basically everything hepatitis in Africa.
Gene therapy: The hybrid AGBT Precision Health meeting will take place September 9-11 in person (vaccination not mandatory) on Coronado Island, CA, and virtually. The focus will be on technologies, implementation, and major research breakthroughs in gene therapy.
Neurology: The FDA is expected to make a decision by September 6 on a nasal spray treatment for acute treatment of migraine with or without aura, Impel NeuroPharma’s Trudhesa (INP-104, dihydroergotamine).
- The Society of Hematologic Oncology (SOHO) meeting will take place September 8-11 virtually. A hybrid meeting had been planned but in mid-August, that plan was scrapped. SOHO claims to be the only international society specific to the field of hematologic malignancies. Topics will include the latest advances in the pathophysiology and therapy of leukemias, myelodysplastic syndromes, lymphomas, myeloproliferative neoplasms, multiple myeloma, and cellular therapy.
- The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer will take place virtually September 8-14. There will be sessions on targeted therapies, the impact of Covid-19 on lung cancer patients, novel approaches to cessation of treatment, biomarkers for immunotherapy, use of real-world data, the outlook for antibody drug conjugates, and, of course, the latest trial data on approved and investigational cancer drugs.
Pain: PAINWeek will take place in-person in Las Vegas September 7-11. Covid-19 vaccination is recommended but not required. Topics to be include: pharmacogenetics, managing chronic back pain, photobiomodulation, neuropathic pain, refractory migraine, and chronic pain after Covid-19.
Regulatory: The FDA is hosting a webcast on September 9 on proteins used as therapeutics and the immunogenicity that creates a “significant impediment” to development of therapeutic proteins. The focus of this lecture is on the tools available for immunogenicity risk-assessment.
Respiratory: The virtual European Respiratory Society (ERS) meeting will continue through September 8.
Urology: The American Urological Association (AUA) annual meeting will take place virtually September 10-13. Expect the usual crossfire debates, sessions on surgical techniques, new guidelines, and everything else new in urology.
Lynne Peterson, Contributing Writer, Senior Writer for Trends-in-Medicine
Cat ID: 707
Topic ID: 74,707,393,497,730,707,111,324,935,35,192,151,725,195,383,925,200,323,706